You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: June 14, 2024

~ Buy the SANCUSO (granisetron) Drug Profile, 2024 PDF Report in the Report Store ~

SANCUSO Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard


When do Sancuso patents expire, and what generic alternatives are available?

Sancuso is a drug marketed by Cumberland and is included in one NDA. There is one patent protecting this drug and one Paragraph IV challenge.

This drug has forty patent family members in thirty-one countries.

The generic ingredient in SANCUSO is granisetron. There are twenty-six drug master file entries for this compound. Two suppliers are listed for this compound. Additional details are available on the granisetron profile page.

DrugPatentWatch® Generic Entry Outlook for Sancuso

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be January 22, 2025. This may change due to patent challenges or generic licensing.

There have been two patent litigation cases involving the patents protecting this drug, indicating strong interest in generic launch. Recent data indicate that 63% of patent challenges are decided in favor of the generic patent challenger and that 54% of successful patent challengers promptly launch generic drugs.

Indicators of Generic Entry

< Available with Subscription >

  Sign Up

Drug patent expirations by year for SANCUSO
Drug Prices for SANCUSO

See drug prices for SANCUSO

DrugPatentWatch® Estimated Loss of Exclusivity (LOE) Date for SANCUSO
Generic Entry Date for SANCUSO*:
Constraining patent/regulatory exclusivity:
NDA:
Dosage:
FILM, EXTENDED RELEASE;TRANSDERMAL

*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Recent Clinical Trials for SANCUSO

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Solasia Pharma K.K.Phase 1
Kyowa Kirin, Inc.Phase 1
PPDPhase 1

See all SANCUSO clinical trials

Pharmacology for SANCUSO
Paragraph IV (Patent) Challenges for SANCUSO
Tradename Dosage Ingredient Strength NDA ANDAs Submitted Submissiondate
SANCUSO Transdermal System granisetron 3.1 mg/24 hrs 022198 1 2015-10-09

US Patents and Regulatory Information for SANCUSO

SANCUSO is protected by one US patents.

Based on analysis by DrugPatentWatch, the earliest date for a generic version of SANCUSO is ⤷  Sign Up.

This potential generic entry date is based on patent ⤷  Sign Up.

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Patents protecting SANCUSO

Transdermal granisetron
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up
Patented Use: USE OF GRANISETRON TRANSDERMAL SYSTEM TO TREAT/PREVENT CHEMOTHERAPY INDUCED NAUSEA AND VOMITING

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Cumberland SANCUSO granisetron FILM, EXTENDED RELEASE;TRANSDERMAL 022198-001 Sep 12, 2008 RX Yes Yes ⤷  Sign Up ⤷  Sign Up Y ⤷  Sign Up
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

EU/EMA Drug Approvals for SANCUSO

Company Drugname Inn Product Number / Indication Status Generic Biosimilar Orphan Marketing Authorisation Marketing Refusal
Kyowa Kirin Holdings B.V. Sancuso granisetron EMEA/H/C/002296
Prevention of nausea and vomiting in patients receiving moderately or highly emetogenic chemotherapy, with or without cisplatin, for up to five consecutive days.Sancuso may be used in patients receiving their first chemotherapy regimen or in patients who have previously received chemotherapy.
Authorised no no no 2012-04-20
>Company >Drugname >Inn >Product Number / Indication >Status >Generic >Biosimilar >Orphan >Marketing Authorisation >Marketing Refusal

International Patents for SANCUSO

See the table below for patents covering SANCUSO around the world.

Country Patent Number Title Estimated Expiration
Costa Rica 7923 GRANISETRON TRANSDERMICO ⤷  Sign Up
Norway 20053663 ⤷  Sign Up
China 1747724 Transdermal granisetron ⤷  Sign Up
Japan 2006516601 ⤷  Sign Up
New Zealand 541103 Adhesive patchs for transdermal administration of granisetron ⤷  Sign Up
>Country >Patent Number >Title >Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.